CN101678029B - 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途 - Google Patents

基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途 Download PDF

Info

Publication number
CN101678029B
CN101678029B CN2008800188649A CN200880018864A CN101678029B CN 101678029 B CN101678029 B CN 101678029B CN 2008800188649 A CN2008800188649 A CN 2008800188649A CN 200880018864 A CN200880018864 A CN 200880018864A CN 101678029 B CN101678029 B CN 101678029B
Authority
CN
China
Prior art keywords
amino
isopropyl
methyl
purine
penta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800188649A
Other languages
English (en)
Chinese (zh)
Other versions
CN101678029A (zh
Inventor
西蒙·格林
希拉格·弗雷姆
伊恩·弗莱明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of CN101678029A publication Critical patent/CN101678029A/zh
Application granted granted Critical
Publication of CN101678029B publication Critical patent/CN101678029B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008800188649A 2007-04-04 2008-04-02 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途 Expired - Fee Related CN101678029B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US92169907P 2007-04-04 2007-04-04
US60/921,699 2007-04-04
GBGB0706633.5A GB0706633D0 (en) 2007-04-04 2007-04-04 Combination
GB0706633.5 2007-04-04
PCT/GB2008/001189 WO2008122779A1 (en) 2007-04-04 2008-04-02 Combination of a purine-based cdk inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders

Publications (2)

Publication Number Publication Date
CN101678029A CN101678029A (zh) 2010-03-24
CN101678029B true CN101678029B (zh) 2012-07-18

Family

ID=38090894

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800188649A Expired - Fee Related CN101678029B (zh) 2007-04-04 2008-04-02 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途

Country Status (6)

Country Link
US (1) US9173938B2 (OSRAM)
EP (1) EP2139486A1 (OSRAM)
JP (1) JP5514099B2 (OSRAM)
CN (1) CN101678029B (OSRAM)
GB (1) GB0706633D0 (OSRAM)
WO (1) WO2008122779A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2405566C9 (ru) 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CA2754917A1 (en) * 2009-03-11 2010-09-16 Research Development Foundation Low molecular weight cyclin e (lmw-e) as a biomarker for personalization of cancer therapies
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
FR2945747A1 (fr) * 2009-05-25 2010-11-26 Centre Nat Rech Scient Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
NO2719708T3 (OSRAM) * 2009-11-13 2018-03-24
PT2509599E (pt) * 2009-12-11 2014-10-15 Niiki Pharma Inc Processo para o tratamento de cancro pancreático
GB201001075D0 (en) * 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
EP2608793B1 (en) * 2010-08-26 2015-07-29 Symphony Evolution, Inc. Use of a receptor-type kinase modulator for treating polycystic kidney disease
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
EP2874631A1 (en) 2012-05-15 2015-05-27 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
ES2733929T3 (es) 2013-07-12 2019-12-03 Piramal Entpr Ltd Una combinación farmacéutica para el tratamiento del melanoma
JP6851978B2 (ja) 2015-04-20 2021-03-31 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ミトコンドリアプロファイリングによるアルボシジブ応答の予測
JP6510075B2 (ja) 2015-05-18 2019-05-08 トレロ ファーマシューティカルズ， インコーポレイテッド バイオアベイラビリティが高いアルボシジブプロドラッグ
EP3331510A4 (en) 2015-08-03 2019-04-03 Tolero Pharmaceuticals, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
CN113750238A (zh) 2015-09-04 2021-12-07 亚狮康私人有限公司 包含瓦尼替尼及抗癌剂之组合疗法
WO2017160568A1 (en) 2016-03-16 2017-09-21 Eli Lilly And Company Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3047557A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
US10624874B2 (en) * 2017-01-10 2020-04-21 Zhejiang Jiachi Development Pharmaceuticals Ltd Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment
WO2019033041A1 (en) * 2017-08-11 2019-02-14 Board Of Regents, The University Of Texas System TARGETING KINASES FOR THE TREATMENT OF CANCER METASTASES
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
KR20200132902A (ko) * 2018-03-13 2020-11-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Egfr 활성화 돌연변이를 갖는 암의 치료 방법
TWI762784B (zh) * 2018-05-23 2022-05-01 大陸商江蘇恒瑞醫藥股份有限公司 Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
GB202000901D0 (en) * 2020-01-22 2020-03-04 Cyclacel Ltd Process
CN116813621A (zh) * 2023-06-08 2023-09-29 江南大学 9h嘌呤类化合物及其药物组合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
EP1558289A1 (en) 2002-11-06 2005-08-03 Cyclacel Limited Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
GB0523040D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
EP2258700A1 (en) * 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ian N.Fleming et al..Combination analysis between seliciclib (CYC202;R-roscovitine) and other molecularly targeted anti-cancer agents in non-small cell lung cancer.《Proc.Amer.Assoc.Cancer Res.》.2006,第47卷 *

Also Published As

Publication number Publication date
JP5514099B2 (ja) 2014-06-04
EP2139486A1 (en) 2010-01-06
GB0706633D0 (en) 2007-05-16
WO2008122779A1 (en) 2008-10-16
JP2010523536A (ja) 2010-07-15
US9173938B2 (en) 2015-11-03
CN101678029A (zh) 2010-03-24
US20100143350A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
CN101678029B (zh) 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途
US11291667B2 (en) Combination therapy involving diaryl macrocyclic compounds
KR20220050143A (ko) Kras-관련 암 치료 방법
KR101668931B1 (ko) 항종양제의 효과 증강제
JP7123806B2 (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
CN111527103A (zh) 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
US20110033453A1 (en) Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
TWI685341B (zh) 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2006508953A (ja) 非受容体チロシンキナーゼのＳｒｃファミリーの阻害剤、および、ゲムシタビンの組み合わせ製品
JP2021536507A (ja) Ｈｅｒ駆動性がんを治療または予防するための化合物、組成物、及び方法
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
JP2008501708A (ja) がんの治療方法
CN101861159A (zh) 改进的抗肿瘤治疗
EP3458064A1 (en) Anticancer combination therapy
US20100063074A1 (en) Cancer Treatment Method
EP4534085A1 (en) Compounds for use in methods of treating cancer
US11390601B2 (en) Conformationally-restricted analogues of sorafenib and regorafenib as selective kinase inhibitors for cancer treatment
JP6553726B2 (ja) 腫瘍治療剤
KR20250105460A (ko) Kras 억제제 및 shp2 억제제를 포함하는 조합 요법
HK40053004A (en) Quinoline derivatives for use in the treatment or prevention of cancer
WO2018106118A1 (en) Treatment of diffuse intrinsic pontine glioma
JP2014034533A (ja) Ｈｓｐ９０阻害剤とｅｇｆｒチロシンキナーゼ阻害剤の組み合わせ
WO2011152515A1 (ja) インドール化合物を含有する抗腫瘍剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120718

Termination date: 20190402

CF01 Termination of patent right due to non-payment of annual fee